SLAB SILICON LABORATORIES INC. Insider Trading

SLAB CEO Johnson Robert Matthew sold 8,024 shares at $216.83 (May 2026); stock near 52-week high, company unprofitable

Johnson Robert Matthew, as President & CEO, sold 8,024 shares of SILICON LABORATORIES INC. for a total of $1,739,843.92 at $216.83 per share, reducing his holdings by 9.1%. The sale occurred near the stock's 52-week high of $218.68, with the company currently unprofitable (net income of $-15,897,000.00 most recent quarter) despite strong annual revenue growth of +34.3%. His cross-ticker track record shows 3 prior sells with an average 90-day return of -1.5% and a well-timed rate of 50.00%, while at SLAB specifically, 1 of his 2 prior measurable sells were well-timed at the 90-day mark. The timing proximity to the 52-week high and the sale size warrant investor attention given the company's profitability challenges, though the CEO retains 80,519 shares post-transaction.

Sr VP WW Sales & Marketing sells 8,000 SLAB shares at $145.23; company faces -25.3% annual revenue decline and $-21.8M annual net loss.

Tolany Brandon, Sr VP WW Sales & Marketing, sold 8,000 shares (8.0K shares) valued at $1,161,840.00, reducing his position from 70,328 shares (70.3K shares) to 62,328 shares (62.3K shares). The sale occurs as SILICON LABORATORIES INC. (SLAB) confronts significant operational headwinds: the company reported a -25.3% annual revenue decline and negative full-year net income of $-21.8M, indicating the firm is unprofitable. The timing places the sale 10.4% below the 52-week high of $158.70, though the stock has gained 5.7% over 30 days and 13.4% over 90 days from earlier depressed levels. A senior sales executive's partial position reduction during a period of contracting revenue and operating losses warrants attention to underlying demand signals and management's confidence in the business turnaround.

SLAB CEO Johnson sells 5,879 shares at $131.20 on 2025-05-16 under 10b5-1 plan; retains 73,688 shares

Johnson Robert Matthew, as President & CEO of Silicon Laboratories, sold 5,879 shares for $771,324.80 as part of a pre-arranged 10b5-1 trading plan, reducing his holdings from 79,567 shares to 73,688 shares (-7.4% vs pre-transaction holdings). As a scheduled transaction under a 10b5-1 plan, this sale reflects a predetermined execution schedule rather than a discretionary decision at a particular market juncture. The CEO retained substantial equity ownership post-transaction, maintaining approximately 73,688 shares in the company.